SCHEMBL435376

SCHEMBL435376

N#CCc1ccc(F)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.41
ENPP2 Q13822 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP11B1 P15538 2/20 0.39
CYP11B2 P19099 2/20 0.39
MMP3 P08254 1/20 0.39
DAO P14920 2/20 0.37
FFAR1 O14842 2/20 0.36
FFAR4 Q5NUL3 1/20 0.36
CYP17A1 P05093 1/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
PTPRC P08575 1/20 0.35
PTPN1 P18031 1/20 0.35
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
CNR1 P21554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28153103 0.86 RIPK1 (0.36) HTTENPP2ALDH1A1CYP11B1CYP11B2
SCHEMBL37791 0.81 DAO (0.41) HTTENPP2ALDH1A1KDM4ETDP1
SCHEMBL5722537 0.81 ENPP2 (0.38) HTTENPP2KDM4ETDP1CYP11B1
SCHEMBL3075770 0.81 CYP11B1 (0.46) ENPP2KDM4ETDP1CYP11B1CYP11B2
SCHEMBL333000 0.81 CYP1A2 (0.44) HTTENPP2KDM4ETDP1CYP11B1
SCHEMBL909509 0.81 SLC6A2 (0.41) ENPP2KDM4ETDP1CYP11B1CYP11B2
SCHEMBL2065860 0.81 CA6 (0.45) HTTENPP2KDM4ETDP1CYP11B1
SCHEMBL8280063 0.81 ENPP2 (0.38) HTTENPP2ALDH1A1KDM4ETDP1
SCHEMBL29700913 0.81 DAO (0.41) HTTENPP2ALDH1A1KDM4ETDP1
SCHEMBL24108188 0.81 CYP11B1 (0.58) ENPP2CYP11B1CYP11B2DAOMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116854668-B Phthalazinone compound, pharmaceutical composition and application thereof 中国药科大学 2025-02-07 CN disclosed
WO-2024174980-A1 COMPOUND CONTAINING DIHYDROPHTHALAZINE AND ALKENYL AND USE THEREOF 正大天晴药业集团股份有限公司 2024-08-29 WO disclosed
CN-116854668-A Phthalazinone compound, pharmaceutical composition and application thereof 中国药科大学 2023-10-10 CN disclosed
EP-3442974-B1 PYRAZOLOPYRIMIDINE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2023-06-07 EP disclosed
EP-3362445-B1 OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2023-01-25 EP disclosed
EP-3362445-B1 OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2023-01-25 EP disclosed
EP-3489569-B1 GAS SUPPLY APPARATUS AND GAS SUPPLY METHOD SHOWA DENKO KK (JP) 2023-01-18 EP disclosed
US-11427907-B2 Gas supply apparatus and gas supply method SHOWA DENKO K.K. (JP) 2022-08-30 US disclosed
US-20220251703-A1 GAS SUPPLY APPARATUS AND GAS SUPPLY METHOD SHOWA DENKO K.K. (JP) 2022-08-11 US disclosed
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2022-01-20 US disclosed
WO-1997019074-A1 SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-05-29 WO disclosed
US-5607947-A Pyrrolidinyl tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 1997-03-04 US disclosed
US-5563133-A NERVOUS SYSTEM DISORDERS ELI LILLY AND COMPANY (US) 1996-10-08 US disclosed
EP-0723959-A1 Heterocyclic compounds as tachykinin receptor antagonists, process for their preparation and pharmaceuticals containing them SANOFI (FR) 1996-07-31 EP disclosed
EP-0714891-A1 Heterocyclic tachykinin receptor antagonists ELI LILLY AND COMPANY (US) 1996-06-05 EP disclosed
EP-0700382-A1 NOVEL N-ARYLALIPHATIC-N-ALKYL-FUNCTIONALISED AMIDES, METHOD FOR THEIR PREPATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1996-03-13 EP disclosed
WO-1995026335-A1 NOVEL N-ARYLALIPHATIC-N-ALKYL-FUNCTIONALISED AMIDES, METHOD FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1995-10-05 WO disclosed
US-5451604-A Useful in organ transplant surgery G. D. SEARLE & CO. (US) 1995-09-19 US disclosed
EP-0669320-A2 Benzoylquinoiline derivatives NIHON BAYER AGROCHEM K.K. (JP) 1995-08-30 EP disclosed
US-3979444-A CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES THE UPJOHN COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS DBH, SLC6A3, SLC6A2 HTT 377/4885ENPP2 4565/4885ALDH1A1 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.